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January 2001 for CML at our institution were retrospectively
reviewed. Imatinib-refractory CML was deﬁned as either lack of
any cytogenetic response (CGR) after at least 6mths of imatinib,
loss of CGR or progression to a more advanced disease stage
(accelerated or blast phase) during imatinib therapy. Using the
EBMT risk score (Lancet 1998; 352: 1087), transplant outcomes
for imatinib refractory CML were compared with all other CML
transplants performed during the same time period. Survival anal-
ysis was performed using the Kaplan-Meier product-limit and
comparison of survival data via the log-rank test.
Results: Of 31 allogeneic transplants (19M; 12F) performed for
CML, 12 had been performed for imatinib refractory CML (no
CGR to imatinib n3; loss of CGR n3; progression to AP n3;
progression to BC n3), 5 in patients with imatinib responsive
CML, and 14 in patients never exposed to imatinib. Median age at
SCT was 40yrs (range 19-63yrs). Donor source included HLA-
matched unrelated donors in 14 cases, HLA-identical siblings in 16
and other matched family donors in 1. Graft source consisted of
PBSC (17), BM (8) and G-BM (6). Conditioning regimens in-
cluded Cy/TBI (20 cases), Bu/Cy (8 cases), Flu/Mel (2 cases) and
Flu/Cy (1 case). CsA  MTX was used as standard GVHD pro-
phylaxis (29), CsA alone (1) and Tacrolimus/Mycophenolate (1).
EBMT risk scores were 1 (4 cases), 2 (6 cases), 3 (8 cases), 4 (5
cases), 5 (3 cases) and 6 (5 cases). At median follow-up post-SCT of
37mths (range 6-64mths), median PFS and OS are not reached; at
2yrs PFS, EFS and OS are 81%, 58% and 61% respectively. For
patients with EBMT risk scores of 1-2 versus 3-4 versus 5-6, OS at
2 yrs post-SCT is 80%, 62% and 38% respectively (p0.03). Based
on EBMT risk score, no signiﬁcant differences in PFS, EFS or OS
were observed when comparing SCT for imatinib-refractory versus
imatinib-responsive / imatinib-naive CML.
Conclusion: Our experience suggests that survival post-SCT for
imatinib-refractory CML is similar to SCT for imatinib-responsive
/ imatinib-naive CML. The EBMT risk score remains useful in
predicting survival post-SCT in imatinib-refractory CML.
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mTOR INHIBITORS (MTI) ARE SYNERGISTIC WITH METHOTREXATE:
AN EFFECTIVE COMBINATION TO BOTH PREVENT POST-HSCT RE-
LAPSE OF ALL AND PREVENT GVHD
Teachey, D.T.1, Brown, V.I.1, Fish, J.1, Reid, G.1, Grupp, S.A.1 1Chil-
dren’s Hospital, Philadelphia, PA.
Many adults and some children with ALL relapse and may
require HSCT for cure. We have previously demonstrated that
MTI, including sirolimus and its ester temsirolimus, are active
against primary human ALL in preclinical models. Recent data in
HSCT indicate efﬁcacy of sirolimus-based GVHD prophylaxis.
Thus, MTI have the potential to both control GVHD and elimi-
nate minimal residual ALL after HSCT. MTI downregulate cyclin
D1 which is involved in dihydrofolate reductase (DHFR) synthesis.
Sensitivity to methotrexate has been shown to correlate with
DHFR expression. Thus, MTI may increase sensitivity of ALL to
methotrexate through decreasing DHFR by increasing turnover of
cyclin D1. We hypothesized MTI and methotrexate would exhibit
synergy against human ALL, suggesting that this combination
could be used as an effective means to prevent both recurrence and
GVHD. We used the relevant preclinical model of NOD/SCID
mice xenografted with primary ALL patient samples. The MTI
sirolimus and temsirolimus signiﬁcantly decrease ALL in xe-
nografted mice with large disease burdens. To test possible syn-
ergy, after establishment of disease, mice were randomized to
treatment with control, temsirolimus (daily or weekly), methotrex-
ate (5mg/kg/weekly) or both drugs combined. Disease was evalu-
ated at weekly intervals by FACS of peripheral blood for CD19/
CD45 ALL cells. The combination of methotrexate and
temsirolimus demonstrated an additive and potentially synergistic
effect. Control mice died after 21 d. Mice treated with temsiroli-
mus or methotrexate alone had initial improvement in ALL fol-
lowed by progression after 4-5 weeks. Mice treated with both drugs
had a complete and durable resolution of peripheral blasts by d 21.
After d 42 treatment was stopped. Mice treated with both drugs
remained in remission and were disease free when sacriﬁced 2
months later in contrast to either single agent treatment group
which died of disease. Kaplan-Meyer analysis of time to progres-
sion demonstrated a statistically signiﬁcant difference, comparing
all treatment arms to control (p 0.01), and comparing the com-
bination of drugs to methotrexate only (p 0.03) and temsirolimus
only (p  0.07) in both samples.
Conclusion: We found methotrexate and MTI are an effective
and potentially synergistic combination in ALL. These agents
could be used to both treat ALL and prevent GVHD, making it an
ideal combination for use as GVHD prophylaxis for ALL patients
undergoing HSCT.
59
GM-CSF SECRETING LEUKEMIA CELL VACCINATIONS AFTER ALLOGE-
NEIC REDUCED-INTENSITY PERIPHERAL BLOOD STEM CELL TRANS-
PLANTATION (SCT) FOR ADVANCED MYELODYSPLASTIC SYNDROME
(MDS) OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
Ho, V.T.1, Dranoff, G.1, Kim, H.1, Pasek, M.1, Cutler, C.1, Koreth, J.1,
Alyea, E.P.1, Antin, J.H.1, Soiffer, R.J.1 1Dana-Farber Cancer Insti-
tute, Boston, MA.
Disease relapse is a frequent cause of treatment failure in patients
undergoing reduced intensity allogeneic SCT for advanced MDS
and AML. Prior studies with GVAX, a cancer vaccine composed of
irradiated autologous myeloblasts modiﬁed to secrete GM-CSF,
suggested anticancer activity in MDS/AML after autologous SCT
or in primary therapy. We investigated the feasibility and safety of
administering GVAX after allogeneic SCT. Patients with MDS-
RAEB or AML with 5% marrow blasts and with a donor
matched at HLA-A,B, DRB1 were eligible. Prior to SCT, autol-
ogous myeloblasts were collected from the marrow or blood and
transfected with an adenovirus vector bearing the GM-CSF gene
to generate the GVAX vaccine. Conditioning consisted of ﬂudara-
bine 30mg/m2/d IV and busulfan 0.8mg/kg IV q12H days -6 to -3
prior to allogeneic PBSC infusion. GVHD prophylaxis included
tacrolimus and mini-methotrexate. GM-CSF (Leukine) 250
mg/m2 SC QD was administered from day 1 until engraftment.
GVAX was administered SC/ID weekly for the ﬁrst three doses,
then q2 weeks for the last three doses starting between day 30 to
45 if there was neutrophil recovery and no grade II-IV acute
GVHD. Tacrolimus was tapered after vaccine completion. Twenty
patients (11 URD, 9 MRD) have been transplanted to date: 14
AML, 4 MDS/RAEB, 2 CML myeloid blast crisis. Median age was
63 (range, 41-71 yrs). Median marrow blast content at SCT was
22% (range, 6-91%). GVAX was successfully generated for all 20
patients. Median vaccine cell dose was 1.0  107 cells (range,
0.1-1.0 107), and median 24-hour GM-CSF secretion by the
vaccine was 8.2 ng/ml/106cells (range 0.4 - 195). Eight patients did
not initiate vaccination due to: poor neutrophil recovery/re-
lapse(4); aGVHD (2); IPS (1); sepsis(1). Two patients were recently
transplanted and have not started vaccination. Among 10 patients
who received GVAX, vaccination was well tolerated. Donor chi-
merism was not adversely affected by vaccination. Six of 10 patients
who started GVAX are alive at a median follow up of 7.5 months
post transplant (range 1-16 mos), and all are in complete remission
(4 AML, 2 MDS-RAEB) between 3 and 16 months after transplant.
Histologic examination of vaccination and leukemia cell DTH sites
revealed signiﬁcant inﬁltration with inﬂammatory cells and eosin-
ophils. These preliminary results suggest GVAX vaccination is safe
and may have anticancer activity in patients with MDS/AML after
allogeneic SCT.
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A HIGH LACTATE DEHYDROGENASE (LDH) LEVEL PREDICTS FOR
SHORTER SURVIVAL FOLLOWING HLA-MATCHED SIBLING BONE MAR-
ROW TRANSPLANT (BMT) FOR PATIENTS WITH ACUTE MYELOGENOUS
LEUKEMIA (AML)
Kalaycio, M.1, Rybicki, L.1, Pohlman, B.1, Dean, R.1, Sweetenham, J.1,
Andresen, S.1, Sobecks, R.1, Sekeres, M.1, Advani, A.1, Brown, S.1,
Bolwell, B.1 1Cleveland Clinic, Cleveland, OH.
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Historically, the most important adverse risk factors for survival
after BMT for AML are Active disease (ActDis), poor-risk cyto-
genetics, and older age. High serum LDH at the time of diagnosis
is an adverse risk factor for survival for AML in the absence of
BMT, but has not been explored as a risk factor in setting of BMT.
We performed a multivariable analysis of these and other potential
risk factors for overall and progression-free survival. From August
1992 to July 2005, we treated 87 patients with AML, who also had
informative cytogenetic studies from the time of diagnosis, with
high-dose busulfan-containing preparative regimens and an HLA-
matched sibling BMT. The median age was 43 years (range 19 to
62). The median LDH level at the time of BMT was 204 U/L
(range 93-1555 U/L; normal 100-220 U/L). Forty-one patients
were in either ﬁrst (n 30) or second complete remission (n11;
CR). 46 patients were with ActDis were treated. The 87 patients
were then classiﬁed according to the SWOG/ECOG (Blood 96:
4075, 2000), MRC (Blood 92:2322, 1998), and CALGB (Blood
100:4325, 2002) cytogenetic classiﬁcation systems. With a median
follow-up of 56.0 months (range 4.5-107.8 months), the median
progression-free survival is 13.5 months for patients in CR1 and
4.1 months for patients in CR2. The progression-free survival of
patients with ActDis was 5.5 months. A Cox proportional hazards
analysis that included gender, age, LDH, disease status, all three
cytogenetic risk groups, preparative regimen, source of stem cells,
and CMV status was performed for overall and progression-free
survival. Signiﬁcant risk factors for shorter survival in univariate
analysis included male gender, LDH 330 U/L (but not LDH
220 U/L or per 100 U/L increase), and peripheral stem cells as
a source of hematopoietic reconstitution (n  7). Surprisingly, a
male donor to a male recipient was also an adverse risk factor
(p0.001). However, in multivariable analysis, only LDH 330
U/L (p0.002), source of stem cells (p0.019), and male donor to
male recipient (p0.001) remained as signiﬁcant adverse risk fac-
tors. In fact, patients with ActDis and an LDH  330 U/L had
similar survival to patients treated in remission, while patients with
ActDis and LDH  330 U/L had signiﬁcantly worse survival. We
conclude that high LDH (1.5X upper limit of normal) at the time
of BMT is a signiﬁcant adverse risk factor for survival after BMT
for AML.
61
NOD2/CARD15 GENE SINGLE NUCLEOTIDE POLYMORPHISMS ARE AS-
SOCIATED WITH SIGNIFICANT INCREASES IN MORTALITY DUE TO
INCREASES IN DISEASE RELAPSE IN RECIPIENTS OF AN UNRELATED
DONOR HAEMATOPOIETIC STEM CELL TRANSPLANT FOR ACUTE LEU-
KAEMIA
Mayor, N.P.1,2, Shaw, B.E.1, Hughes, D.A.2, Maldonado-Torres, H.1,2,
Madrigal, J.A.1,2, Keshav, S.3, Marsh, S.G.E.1,2 1Anthony Nolan Re-
search Institute, London, United Kingdom; 2Department of Haematol-
ogy, Royal Free and Univeristy College London School of Medicine,
London, United Kingdom; 3Department of Medicine, Royal Free and
Univeristy College London School of Medicine, London, United Kingdom.
SNPs of the Nucleotide-binding Oligomerisation Domain 2/
Caspase Recruitment Domain 15 (NOD2/CARD15) gene, are
implicated in inﬂammatory disorders, particularly Crohn’s Dis-
ease, Blau syndrome and in the onset and pathogenicity of malig-
nant diseases. NOD2/CARD15 SNPs have also been implicated
with signiﬁcant increases in Transplant Related Mortality and
clinically signiﬁcant acute Graft versus Host Disease post-Haema-
topoietic Stem Cell Transplant (HSCT).
NOD2/CARD15 genotyping was performed on 196 patients
diagnosed with Acute Leukaemia and their volunteer Unrelated
Donors (UD). Transplants occurred between 1996 and 2003 at 25
UK transplant centres. Diagnoses were Acute Lymphoblastic Leu-
kaemia (98/196, 50%) and Acute Myeloid Leukaemia (98/196,
50%). Recipients and donors were a 10/10 HLA allele match
(HLA-A, -B, -C, -DRB1, and -DQB1) in 64% of pairs. Of these,
16% were a 12/12 HLA allele match (also matched at HLA-
DPB1). Myeloablative conditioning regimens were used in 78% of
cases. T-cell depletion was included in 83% of conditioning pro-
tocols, mostly using in-vivo alemtuzumab. Peripheral blood stem
cells were used as a graft in 19% of transplants, with the remaining
81% using bone marrow. Two forms of post-transplant immuno-
suppression predominated, Cyclosporine A and Methotrexate
(47%) and Cyclosporine A alone (31%).
SNPs of the NOD2/CARD15 gene within an UD-HSCT pair
resulted in a signiﬁcant increase in disease relapse and mortality.
The estimated two-year incidence of disease relapse was 43% in
wild type pairs as compared to 70% in pairs with NOD2/CARD15
SNPs (Log rank, P0.0003). The estimated three-year overall
survival was 22% and 44% for pairs with and without NOD2/
CARD15 polymorphisms respectively (Log rank, P0.0087).
These ﬁndings persisted in multivariate analysis. NOD2/CARD15
genotype was found to be the most signiﬁcant factor for an adverse
outcome other than being transplanted in a disease stage of relapse.
In contrast to previous ﬁndings, the presence of NOD2/
CARD15 SNPs in an Acute Leukaemia UD-HSCT pair results in
a signiﬁcant increase in disease relapse and subsequently a decrease
in mortality. These novel data show an important role for NOD2/
CARD15 genotyping in transplantation and suggest a possible
effect of the NOD2 protein in alloreactivity and tumour surveil-
lance. Genotyping recipients and donors prior to transplant may
allow for prediction of transplant outcome, and thus present crit-
ical information for donor selection.
LYMPHOMA/MULTIPLE MYELOMA
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TWO-YEAR FOLLOW-UP RESULTS AT THE M.D. ANDERSON HOSPITAL
WITH REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTA-
TION WITH FLUDARABINE-MELPHALAN AS PREPARATIVE REGIMEN IN
RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA
Anderlini, P.1, Saliba, R.1, Acholonu, S.1, Giralt, S.A.1, Khouri, I.F.1,
Andersson, B.1, De Lima, M.1, Hosing, C.1, Champlin, R.E.1 1M.D.
Anderson Hospital, Houston, TX.
Fifty-eight patients with relapsed or refractory Hodgkin’s lym-
phoma (HL) underwent allogeneic stem cell transplantation (allo-
SCT) following a reduced-intensity conditioning (RIC) regimen
from a matched related donor (MRD; n25) or a matched unre-
lated donor (MUD; n33). The median age was 32 years (range
19-59). Forty-eight (83%) patients had received a prior autologous
(auto) SCT. The median time to progression after auto-SCT was
ﬁve months (1-34). Disease status at SCT was sensitive relapse
(n30) or refractory relapse (n28).The conditioning regimen
employed was ﬂudarabine (125-130 mg/m sq over 4-5 days), mel-
phalan (140 mg/m sq IV over 2 days) (FM) and antithymocyte
globulin (thymoglobulin 6 mg/kg over 3 days) was added for the
most recent fourteen MUD transplants. Chimerism studies indi-
cated 100% donor-derived engraftment in all patients (100%).
Cumulative 100-day and 2-year transplant-related mortality
(TRM) were 7% and 15%, respectively, (100-day TRM MRD vs.
MUD 6% vs. 8%, pns; 2-year MRD vs. MUD 13% vs. 16%,
pns). The cumulative incidence of acute (grade II-IV) GVHD
(ﬁrst 100 days) was 28% (MRD vs. MUD 12% vs. 39%, p0.04).
The cumulative incidence of chronic GVHD at any time was 74%
(MRD vs. MUD 57% vs. 89%, p0.003). Fourteen pts (24%)
received a total of 25 (range 1-5) donor leukocyte infusions (DLIs)
for disease progression/relapse (PD). Five of them (35%) received
chemotherapy as well, and nine (64%) developed acute GVHD
after the DLI. Thirty-six patients (62%) are alive (23 in remission)
with a median follow-up of 24 months (4-78). The f/up is 23
months (4-53) for alive pts always in remission. Twenty-two pa-
tients (38%) expired, and relapse-related mortality was 24%. Pro-
jected 2-year overall (OS) and progression-free (PFS) survival are
64% (49-76) and 32% (20-45), with 2-year projected PD at 55%
(43-70). There was no statistically signiﬁcant difference between
MRD and MUD transplants with regard to OS (p0.1), PFS
(p0.9) and PD (p0.8). There was a trend for the response status
prior to allo-SCT (complete response, complete response unde-
ﬁned vs. all others) to favorably impact PFS (p0.07) and PD
(p0.049), but not OS (p0.4). Partial responders and patients
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